DXR vs. LNSR, AMIX, LUCD, ICCM, SEPA, XAIR, CTCX, MODD, CTSO, and APYX
Should you be buying Daxor stock or one of its competitors? The main competitors of Daxor include LENSAR (LNSR), Autonomix Medical (AMIX), Lucid Diagnostics (LUCD), IceCure Medical (ICCM), SEP Acquisition (SEPA), Beyond Air (XAIR), Carmell (CTCX), Modular Medical (MODD), Cytosorbents (CTSO), and Apyx Medical (APYX). These companies are all part of the "surgical & medical instruments" industry.
LENSAR (NASDAQ:LNSR) and Daxor (NASDAQ:DXR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations, community ranking and profitability.
Daxor has a net margin of 0.00% compared to Daxor's net margin of -27.57%. LENSAR's return on equity of 0.00% beat Daxor's return on equity.
In the previous week, LENSAR and LENSAR both had 4 articles in the media. LENSAR's average media sentiment score of 0.76 beat Daxor's score of 0.69 indicating that Daxor is being referred to more favorably in the news media.
40.2% of LENSAR shares are held by institutional investors. Comparatively, 1.3% of Daxor shares are held by institutional investors. 66.0% of LENSAR shares are held by insiders. Comparatively, 60.6% of Daxor shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
LENSAR currently has a consensus target price of $8.00, indicating a potential upside of 84.76%. Given Daxor's higher possible upside, analysts plainly believe LENSAR is more favorable than Daxor.
LENSAR received 5 more outperform votes than Daxor when rated by MarketBeat users.
LENSAR has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500. Comparatively, Daxor has a beta of -0.45, suggesting that its stock price is 145% less volatile than the S&P 500.
Daxor has lower revenue, but higher earnings than LENSAR.
Summary
LENSAR beats Daxor on 7 of the 11 factors compared between the two stocks.
Get Daxor News Delivered to You Automatically
Sign up to receive the latest news and ratings for DXR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DXR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
